The classification of neuroendocrine neoplasms (NENs) differs between organ systems and
currently causes considerable confusion. A uniform classification framework for NENs at any …

Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded
to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable …

Abstract The European Society of Endocrinology (ESE) survey reported on the largest cohort
of 125 aggressive pituitary tumours (APT) and 40 pituitary carcinomas (PC). Whilst the …

Pituitary adenomas are unique in multiple ways. They are rarely malignant in terms of
metastases; yet, they may be aggressive. Their cancerous potential is defined in a classic …

At least 50% of surgically resected non-functioning pituitary adenomas (NFPA) recur. Either
early or late adjuvant radiotherapy is highly efficacious in controlling recurrent NFPA but …

Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine
neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in …

Temozolomide (TMZ) has recently been recommended as the first line chemotherapy in
patients with aggressive pituitary tumors (APT) and pituitary carcinomas (PC) not controlled …

Cushing's disease is the most frequent form of hypercortisolism and is caused by
hypophyseal corticotroph adenomas secreting excessive amounts of adrenocorticotropic …

We describe the 20-year course of a 63-year-old male with a macroprolactinoma that
acquired resistance to treatment and aggressive behavior after a 4-year successful …

Background: Pituitary carcinoma (PC) is an aggressive neuroendocrine tumor diagnosed
when a pituitary adenoma (PA) becomes metastatic. PCs are typically resistant to therapy …